Kanaji Nobuhiro, Sakai Kenichiro, Ueda Yutaka, Miyawaki Hiroshi, Ishii Tomoya, Watanabe Naoki, Kita Nobuyuki, Kadota Kyuichi, Kadowaki Norimitsu, Bandoh Shuji
Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Kagawa, Japan.
Lung Cancer. 2017 Jun;108:126-133. doi: 10.1016/j.lungcan.2017.03.013. Epub 2017 Mar 27.
Small cell lung cancer (SCLC) can be subgrouped into central and peripheral types according to the location of the primary lesion. However, the clinical differences between these two types remain unclear. This study compared their clinical features.
Data on 231 patients with pathologically diagnosed SCLC were retrospectively subgrouped into central or peripheral types. Progression-free survival (PFS), overall survival (OS), treatments, responses to first-line therapy, and frequency of interstitial lung disease (ILD) were compared between the two groups.
Of the 231 patients, 101 (44%) had central-type and 130 (56%) had peripheral-type SCLC. Peripheral-type SCLC was associated with a better performance status, higher frequency of ILD, and higher rate of limited disease stage. Patients with peripheral-type SCLC had a significantly longer OS than did those with central-type SCLC (median, 502 vs 370days, respectively; p=0.0186). Tumor location was not associated with PFS. PFS was poorer in patients with than without ILD (median, 143 vs 213days, respectively; p=0.0038), as was OS (median, 245 vs 545days, respectively; p=0.0014). Among patients without ILD, OS was longer in those with peripheral- than central-type tumors (median, 662 vs 421days, respectively; p=0.0074). Surgical resection was more often chosen for peripheral-type tumors, and this was one reason for the prolonged survival. There was no difference in the response to chemotherapy and/or radiotherapy between central- and peripheral-type SCLC. Multivariate analysis by a Cox proportional hazards model showed that male sex, a poor performance status, extensive disease, the presence of ILD, an elevated serum neuron-specific enolase concentration, and central-type SCLC were poor prognostic factors for OS.
Peripheral-type SCLC is associated with better OS and a higher frequency of ILD than is central-type SCLC. The presence of ILD is a poor prognostic factor for both PFS and OS.
小细胞肺癌(SCLC)可根据原发灶位置分为中央型和周围型。然而,这两种类型之间的临床差异仍不明确。本研究比较了它们的临床特征。
对231例经病理诊断为SCLC的患者的数据进行回顾性分析,将其分为中央型或周围型。比较两组的无进展生存期(PFS)、总生存期(OS)、治疗方法、一线治疗反应以及间质性肺疾病(ILD)的发生率。
在231例患者中,101例(44%)为中央型SCLC,130例(56%)为周围型SCLC。周围型SCLC与较好的体能状态、较高的ILD发生率以及较高的疾病局限期比例相关。周围型SCLC患者的OS明显长于中央型SCLC患者(中位生存期分别为502天和370天;p=0.0186)。肿瘤位置与PFS无关。有ILD的患者PFS较差(中位生存期分别为143天和213天;p=0.0038),OS也较差(中位生存期分别为245天和545天;p=0.0014)。在无ILD的患者中,周围型肿瘤患者的OS长于中央型肿瘤患者(中位生存期分别为662天和421天;p=0.0074)。周围型肿瘤更常选择手术切除,这是生存期延长的一个原因。中央型和周围型SCLC对化疗和/或放疗的反应没有差异。Cox比例风险模型的多因素分析显示,男性、体能状态差、疾病广泛、存在ILD、血清神经元特异性烯醇化酶浓度升高以及中央型SCLC是OS的不良预后因素。
与中央型SCLC相比,周围型SCLC的OS更好,ILD发生率更高。ILD的存在是PFS和OS的不良预后因素。